share_log

Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $28

Benzinga ·  May 7 08:51

Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and lowers the price target from $39 to $28.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment